metaPreg - Lansoprazole during pregnancy

Lansoprazole

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.01 [0.90, 1.14]	0%	4 studies	114,826	7,475	not evaluable	ROB
Major congenital malformations	1.01 [0.90, 1.14]	0%	4 studies	114,826	7,475	not evaluable	ROB
Hypospadias	1.57 [0.70, 3.51]	13%	3 studies	3,342	3,309	not evaluable	ROB
Atrial septal defect	49.70 [1.92, 1288.78]	-	1 study	1	13	not evaluable	ROB
8 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Low birth weight (< 2500g)	0.91 [0.83, 1.00]	-	1 study	104,538	8,678	not evaluable	ROB
1 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Infant asthma	1.70 [1.38, 2.09]	-	1 study		346	not evaluable	ROB
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
Ectopic pregnancy	-	-	0 study
Elective/induced termination of pregnancy	3.96 [1.65, 9.51]	-	1 study	34	62	not evaluable	ROB
2 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB
1 non statistically significant endpoints reported in only one study